The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

Gibson C. M. , Halaby R., Korjian S., Daaboul Y., Arbetter D. F. , Yee M. K. , ...More

AMERICAN HEART JOURNAL, vol.185, pp.93-100, 2017 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 185
  • Publication Date: 2017
  • Doi Number: 10.1016/j.ahj.2016.12.004
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.93-100


Background The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.